Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to ...
SOUTH PLAINFIELD, N.J., Sept. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio prioritization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results